HER-2 Positive Breast Cancer Active Not Recruiting Phase 2 Trials for Trastuzumab (DB00072)

IndicationStatusPhase
DBCOND0042425 (HER-2 Positive Breast Cancer)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02675231A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast CancerTreatment
NCT02488564A Study of Liposomal Doxorubicin + Docetaxel + Trastuzumab + Metformin in Operable and Locally Advanced HER2 Positive Breast CancerTreatment
NCT01340430Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast CancerTreatment